GB0524428D0 - Medicinal use of receptor ligands - Google Patents

Medicinal use of receptor ligands

Info

Publication number
GB0524428D0
GB0524428D0 GBGB0524428.0A GB0524428A GB0524428D0 GB 0524428 D0 GB0524428 D0 GB 0524428D0 GB 0524428 A GB0524428 A GB 0524428A GB 0524428 D0 GB0524428 D0 GB 0524428D0
Authority
GB
United Kingdom
Prior art keywords
receptor ligands
medicinal use
medicinal
ligands
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0524428.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
7TM Pharma AS
Original Assignee
7TM Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 7TM Pharma AS filed Critical 7TM Pharma AS
Priority to GBGB0524428.0A priority Critical patent/GB0524428D0/en
Publication of GB0524428D0 publication Critical patent/GB0524428D0/en
Priority to US12/094,907 priority patent/US20080312220A1/en
Priority to BRPI0619260-2A priority patent/BRPI0619260A2/pt
Priority to CNA2006800441506A priority patent/CN101316829A/zh
Priority to CA002631652A priority patent/CA2631652A1/en
Priority to EP06829107A priority patent/EP1960376A1/en
Priority to EA200801494A priority patent/EA200801494A1/ru
Priority to KR1020087012911A priority patent/KR20080072688A/ko
Priority to AU2006319462A priority patent/AU2006319462A1/en
Priority to JP2008542640A priority patent/JP2009517417A/ja
Priority to PCT/EP2006/011216 priority patent/WO2007062773A1/en
Priority to ZA200804687A priority patent/ZA200804687B/xx
Priority to EC2008008479A priority patent/ECSP088479A/es
Priority to SV2008002925A priority patent/SV2009002925A/es
Priority to CR10034A priority patent/CR10034A/es
Priority to HN2008000817A priority patent/HN2008000817A/es
Priority to NO20082917A priority patent/NO20082917L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
GBGB0524428.0A 2005-11-30 2005-11-30 Medicinal use of receptor ligands Ceased GB0524428D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB0524428.0A GB0524428D0 (en) 2005-11-30 2005-11-30 Medicinal use of receptor ligands
BRPI0619260-2A BRPI0619260A2 (pt) 2005-11-30 2006-11-22 derivados de oxadiazol com atividade de receptor ctrh2, composição farmacêutica que os compreende e uso dos referidos derivados
AU2006319462A AU2006319462A1 (en) 2005-11-30 2006-11-22 Oxadiazole derivatives with CRTH2 receptor activity
PCT/EP2006/011216 WO2007062773A1 (en) 2005-11-30 2006-11-22 Oxadiazole derivatives with crth2 receptor activity
CNA2006800441506A CN101316829A (zh) 2005-11-30 2006-11-22 具有crth2受体活性的噁二唑衍生物
CA002631652A CA2631652A1 (en) 2005-11-30 2006-11-22 Oxadiazole derivatives with crth2 receptor activity
EP06829107A EP1960376A1 (en) 2005-11-30 2006-11-22 Oxadiazole derivatives with crth2 receptor activity
EA200801494A EA200801494A1 (ru) 2005-11-30 2006-11-22 Производные оксадиазола с активностью crth2 рецептора
KR1020087012911A KR20080072688A (ko) 2005-11-30 2006-11-22 옥사디아졸 유도체
US12/094,907 US20080312220A1 (en) 2005-11-30 2006-11-22 Oxadiazole Derivatives with Crth2 Receptor Activity
JP2008542640A JP2009517417A (ja) 2005-11-30 2006-11-22 Ｃｒｔｈ２レセプター活性を有するオキサジアゾール誘導体類
ZA200804687A ZA200804687B (en) 2005-11-30 2008-05-29 Oxadiazole derivatives with CRTH2 receptor activity
EC2008008479A ECSP088479A (es) 2005-11-30 2008-05-29 Derivados de oxadiazol
SV2008002925A SV2009002925A (es) 2005-11-30 2008-05-30 Derivados de oxadiazol
CR10034A CR10034A (es) 2005-11-30 2008-05-30 Derivados de oxadiazol
HN2008000817A HN2008000817A (es) 2005-11-30 2008-06-02 Derivados de oxadiazol
NO20082917A NO20082917L (no) 2005-11-30 2008-06-27 Oksadiazolderivater med CRTH2-reseptoraktivitet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0524428.0A GB0524428D0 (en) 2005-11-30 2005-11-30 Medicinal use of receptor ligands

Publications (1)

Publication Number Publication Date
GB0524428D0 true GB0524428D0 (en) 2006-01-11

Family

ID=35685792

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0524428.0A Ceased GB0524428D0 (en) 2005-11-30 2005-11-30 Medicinal use of receptor ligands

Country Status (17)

Country Link
US (1) US20080312220A1 (enExample)
EP (1) EP1960376A1 (enExample)
JP (1) JP2009517417A (enExample)
KR (1) KR20080072688A (enExample)
CN (1) CN101316829A (enExample)
AU (1) AU2006319462A1 (enExample)
BR (1) BRPI0619260A2 (enExample)
CA (1) CA2631652A1 (enExample)
CR (1) CR10034A (enExample)
EA (1) EA200801494A1 (enExample)
EC (1) ECSP088479A (enExample)
GB (1) GB0524428D0 (enExample)
HN (1) HN2008000817A (enExample)
NO (1) NO20082917L (enExample)
SV (1) SV2009002925A (enExample)
WO (1) WO2007062773A1 (enExample)
ZA (1) ZA200804687B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2327693B9 (en) 2007-12-14 2012-10-24 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
AU2010212970A1 (en) 2009-02-12 2011-08-18 Merck Serono S.A. Phenoxy acetic acid derivatives
WO2011108534A1 (ja) * 2010-03-01 2011-09-09 Shinozawa Takao プロスタグランディンＤ２とその代謝物およびクレアチニンの分析による筋萎縮性側索硬化症（ＡＬＳ）の診断方法、治療における薬物の有効性を評価する方法および尿中のｔＰＧＤＭ濃度を推測するシステム
EP2590944B1 (en) 2010-07-05 2015-09-30 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
ES2624379T3 (es) 2011-12-21 2017-07-14 Idorsia Pharmaceuticals Ltd Derivados de heterociclilo y su uso como moduladores del receptor de prostaglandina D2
US9169270B2 (en) 2012-07-05 2015-10-27 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
CN104744429B (zh) * 2013-12-27 2016-09-28 启东韶远化学科技有限公司 一种环并[b]噻吩-3(2H)-酮-1,1-二氧化物的简单合成方法
WO2016202341A1 (en) * 2015-06-15 2016-12-22 Nmd Pharma Aps Compounds for use in treating neuromuscular disorders
EP3595777A4 (en) * 2017-03-14 2021-01-20 Dana-Farber Cancer Institute, Inc. LOW MOLECULAR SENSITIVITY OF BAX ACTIVATION FOR INDUCING CELL DEATH
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US12440477B2 (en) 2017-12-14 2025-10-14 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
TWI780281B (zh) * 2017-12-14 2022-10-11 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物
EP3986878B1 (en) * 2019-06-19 2024-09-25 NMD Pharma A/S Process for the preparation of clc-1 chloride channel inhibitors
PH12021552771A1 (en) 2019-06-19 2022-10-17 Nmd Pharma As Compounds for the treatment of neuromuscular disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
US7534897B2 (en) 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
JPWO2003097042A1 (ja) 2002-05-16 2005-09-15 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗剤
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
EP2336113A1 (en) * 2004-05-29 2011-06-22 7TM Pharma A/S CRTH2 Receptor Ligands for Medical Use

Also Published As

Publication number Publication date
EP1960376A1 (en) 2008-08-27
BRPI0619260A2 (pt) 2011-09-27
KR20080072688A (ko) 2008-08-06
AU2006319462A1 (en) 2007-06-07
ECSP088479A (es) 2008-07-30
HN2008000817A (es) 2010-10-01
CN101316829A (zh) 2008-12-03
JP2009517417A (ja) 2009-04-30
WO2007062773A1 (en) 2007-06-07
CR10034A (es) 2008-07-22
CA2631652A1 (en) 2007-06-07
US20080312220A1 (en) 2008-12-18
ZA200804687B (en) 2009-10-28
SV2009002925A (es) 2009-01-05
NO20082917L (no) 2008-08-29
EA200801494A1 (ru) 2008-12-30

Similar Documents

Publication Publication Date Title
SI3424932T1 (sl) Boronoftalidi za terapevtsko uporabo
GB0625659D0 (en) Therapeutic compounds and their use
IL182614A0 (en) Pharmaceutical compounds
GB0416728D0 (en) Medicinal use of receptor ligands
GB0524428D0 (en) Medicinal use of receptor ligands
IL181229A0 (en) Noncardiotoxic pharmaceutical compounds
PL1957073T3 (pl) Substancja lecznicza
IL179462A0 (en) Use of the receptor gpr86
EP1806147A4 (en) USE OF IMMUNOSUPPRESSIVE RECEPTOR
GB0524427D0 (en) Use of receptor ligands in threapy
GB0424742D0 (en) Pharmaceutical compounds
GB0501655D0 (en) Therapeutic use
GB0428554D0 (en) Pharmaceutical compounds
GB0414195D0 (en) Medicinal use of receptor ligands
GB0424016D0 (en) Medicinal use of receptor ligands
GB0414197D0 (en) Medicinal use of receptor ligands
GB0424015D0 (en) Medicinal use of receptor ligands
GB0412198D0 (en) Medicinal use of receptor ligands
GB0425413D0 (en) Medicinal use of receptor ligands
GB0424018D0 (en) Medicinal use of receptor ligands
GB0414196D0 (en) Medicinal use of receptor ligands
GB0414194D0 (en) Medicinal use of receptor ligands
GB0710682D0 (en) Medicinal use of receptor ligands
GB0614538D0 (en) Therapeutic Compounds And Their Use
GB0500826D0 (en) Pharmaceutical use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)